Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc. (KPTI)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2024
Context: The Company entered into a series of material definitive agreements to restructure its capital, limit aggregate indebtedness, extend debt maturities, and secure additional working capital. The transactions involve a new senior secured term loan, an exchange of existing convertible notes for new secured notes and warrants, and an amendment to its financing agreement with HealthCare Royalty Management, LLC (HCRx).
Key Financial Metrics and Capital Structure
- New Term Loan: $100.0 million senior secured term loan facility.
- Interest Rate: Variable (Term SOFR + 9.25%, with a 3.00% floor).
- Maturity: May 8, 2028.
- Amortization: Quarterly cash payments of 6.25% of aggregate principal commencing 24 months after closing.
- Use of Proceeds: Approximately $49.5 million to repay HCRx obligations; remainder for general corporate purposes and transaction fees.
- Note Exchange: Approximately $148.0 million of existing unsecured 2025 Notes exchanged for:
- New Notes: Approximately $111.0 million aggregate principal of 6.00% Convertible Senior Notes due 2029 (secured, second-lien).
- Warrants: Warrants to purchase up to approximately 46.0 million shares of common stock.
- HCRx Financing Amendment:
- Payments Made: $49.5 million cash, $15.0 million Term Loan note, and $5.0 million New Notes delivered to HCRx.
- Remaining Obligation: Maximum amount owing to HCRx reduced to approximately $128.3 million.
- Subordination: HCRx debt subordinated to the new Term Loan and pari passu with the New Notes.
- Liquidity Covenant: The Company must maintain liquidity of at least $25.0 million at all times under both the Credit Agreement and the Indenture.
Material Changes Versus Prior Period
This filing represents a significant restructuring of the Company's debt profile compared to the prior period:
- Debt Maturity Extension: Existing 2025 Notes (unsecured) are being replaced with 2029 Notes (secured) and a 2028 Term Loan, extending the maturity horizon by 4 to 5 years.
- Security Status: The Company has moved from unsecured convertible notes to secured obligations (first priority for Term Loan, second priority for New Notes) backed by substantially all assets of the Company and material subsidiaries.
- Interest Rate Structure: Introduction of a variable rate Term Loan with a high spread (9.25% over SOFR) and a fixed 6.00% rate on New Notes, replacing the previous 3.00% rate on 2025 Notes.
- Equity Dilution Potential: Issuance of warrants for up to 46.0 million shares and conversion features on New Notes (initial conversion price $2.25, representing a ~105% premium to the May 7, 2024 stock price of $1.10).
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The transactions are designed to provide additional working capital and extend the maturity of indebtedness. The Company intends to use proceeds for general corporate purposes.
Risks and Covenants:
- Asset Restrictions: The Company is prohibited from exclusively licensing, selling, or disposing of U.S. rights to oncology indications of selinexor.
- Events of Default: Includes withdrawal of approval for selinexor (current indication with bortezomib and dexamethasone), payment defaults, bankruptcy, and cross-defaults.
- Prepayment Penalties: Significant prepayment premiums apply if the Term Loan is repaid early (5.00% before the first anniversary, declining to 0% after the third anniversary).
- Registration Rights: The Company must file a registration statement for warrant shares within 45 days of the New Notes Closing Date. Failure to do so triggers liquidated damages of 1% of the notional amount per 30-day period.
Key Facts for Investor Verification
- Verify the exact closing date of the Exchange Agreements (expected on or around May 13, 2024) and the final principal amounts of the New Notes and Warrants issued.
- Confirm the Company's current liquidity position to ensure compliance with the new $25.0 million minimum liquidity covenant.
- Monitor the status of the registration statement for the 46.0 million warrant shares to avoid potential liquidated damages.
- Review the specific terms of the "Redemption Make-Whole Consideration" and "Fundamental Change Make-Whole Adjustment" in the New Notes Indenture.
- Assess the impact of the new variable interest rate (SOFR + 9.25%) on future interest expense given current and projected interest rate environments.